Valeant offers to increase lender interest payments in exchange for amendment
Reuters
Published Aug 09, 2016 10:02PM ET
Updated Aug 09, 2016 10:20PM ET
Valeant offers to increase lender interest payments in exchange for amendment
NEW YORK (RLPC) - Valeant Pharmaceuticals (NYSE:VRX) International (TO:VRX) is offering to pay lenders a higher interest rate in order to obtain an amendment to its debt agreement that would loosen one of its covenants, according to sources.
The company previously obtained an amendment earlier this year to help stave off default, allowing it additional time to file its financial statements with securities regulators. Joe Papa, Valeant's chief executive officer, said on a conference call Tuesday that the company would seek to modify the interest financial maintenance coverage covenant on its bank debt.
In addition to loosening its interest coverage ratio covenant, Valeant also wants to change some of the language around asset sales, sources said. There will be a lender call Wednesday at 3 pm to discuss the proposed amendment.
In return for the amendment, the company is offering to increase the interest rate it pays lenders by 50 basis points, according to sources. It is also offering to pay a 25 basis points amendment fee.
Valeant had a $1.35 billion revolving line of credit, a $1.424 billion A-3 tranche A term loan, an $835.6 million A-4 tranche A term loan, a $1.053 billion D-2 tranche B term loan, an $808.9 million C-2 tranche B term loan, a $2.45 billion E-1 tranche B term loan and a $3.88 billion F tranche B term loan as of June 30, according to an earnings release. The company also had $19.26 billion of senior notes.
Lenders must decide if they will agree to the amendment by August 17, the sources said. Barclays (LON:BARC) is arranging the amendment.
A Barclays spokesperson and a spokesperson for Valeant did not immediately return e-mails seeking comment.
The company, which reported earnings Tuesday, said it repaid $1.29 billion of debt in 2016, according to an earnings presentation. Valeant said it had a net loss of $302 million in the second quarter compared to a net loss of $53 million in the second quarter of 2015, according to the earnings release.
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.